Stock & Company Details
Aclaris Therapeutics Inc $ACRS
Price:
N/A
N/A
140M
$583M
52 Week High:
N/A
10 Day Average Volume:
N/A
-7.12
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
ACRS technical indicators
Latest Aclaris Therapeutics Inc (ACRS) indicator readings as of 2026-10-29.
ACRS's 14-day RSI is 46.0, in neutral territory. At $3.99 it is trading 11.9% below its 200-day moving average of $4.53, and below its 50-day average of $4.93. Price sits in the middle of its Bollinger Bands ($3.19 to $4.29). ADX reads 39.0, indicating a trending market.
Overview
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Finance Bot
Ask your questions
Start by typing a question below.
